1. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS. (12th June 2019) Authors: Rajeeve, S.; Bobillo, S.V.; Zelenetz, A.D.; Straus, D.J.; Palomba, M.L.; Noy, A.; Horwitz, S.M.; Moskowitz, A.J.; Hamlin, P.A.; Matasar, M.J.; Kumar, A.; Batlevi, C.L.; von Keudell, G.; Yahalom, J.; Dogan, A.; Drill, E.; Younes, A.; Joffe, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. (June 2017) Authors: Herrera, A.F.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; Lacasce, A.S.; Ansell, S.M.; Moskowitz, C.H.; Fenton, K.; Ogden, C.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. (12th June 2019) Authors: Zinzani, P.L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P.M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N.A.; Mehta‐Shah, N.A.; Manley, T.; Francis, S.; Sharma, M.; Moskowitz, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Outcomes and prognostic factors in African American/black patients with mycosis fungoides and Sézary syndrome. (2019) Authors: Geller, S.; Lebowitz, E.; Pulitzer, M.P.; Horwitz, S.M.; Moskowitz, A.J.; Dusza, S.; Myskowski, P.L. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗